January 17, 2012Date Released: 17 January 2012
CASE CCC IN THE NEWS
New Treatment May be Able to Give Some Cancer Patients More Time
Ohio Parents Admit Denying Ailing Son Medical Care
Local Boy Chosen as St. Baldrick's Foundation Ambassador
Exploradio - The Other Side of Evolution
MARK YOUR CALENDARSCancer Center Seminar Series: Biomarker- Directed Therapy of NSCLC
Friday, January 20
Please join us Friday, January 20 for the next Cancer Center Seminar Series where Dr. David Carbone will present Biomarker- Directed Therapy of NSCLC.
Dr. Carbone is Professor of Medicine, Cell Biology, and Cancer Biology at the Vanderbilt University Medical Center, and Director of the Thoracic/Head and Neck Cancer Program at the Vanderbilt-Ingram Cancer Center. He is also Director and Principal Investigator of the Vanderbilt Specialized Program of Research Excellence (SPORE) in Lung Cancer and the Strategic Partnering to Evaluate Cancer Signatures UO1 consortium.
His research interests, grant support and publications have been focused on lung cancer, and specifically proteomic and expression array signature development, lung cancer genetics, cancer immunotherapy, tumor-associated immunosuppression mechanisms and gene therapy. Recent research directions include molecular profiling of lung cancers and preneoplasias, especially the use of mass spectrometry-based proteomics. He as over 150 peer-reviewed publications and review articles, has served on several NCI grant review panels, including the clinical program project parent committee, and has continuous NCI funding since early in his career. He has served on organizing committees for both ASCO and AACR and the Board of Scientific Counselors for the NCI, is currently Chair of the Lung Biology subcommittee for the Eastern Cooperative Oncology Group and on the Board of Directors of the International Association for the Study of Lung Cancer (IASLC).
ANNOUNCEMENTSCooke Honored with Professorship
Dr. Kenneth R. Cooke was recently honored as the Ohio Eminent Scholar for Stem Cell and Regenerative Medicine and the Dr. Leonard C. Hanna Professor at Case Western Reserve University School of Medicine. Dr. Cooke was recruited as the Ohio Eminent Scholar for Stem Cell and Regenerative Medicine in 2007 for his expertise in stem cell transplantation and the two most frequent and severe complications following this procedure: graft-versus-host disease (GVHD) and a frequently fatal form of lung disease known as idiopathic pneumonia syndrome (IPS). Dr Cooke also brings outstanding leadership to the University Hospitals Rainbow Babies and Children's Hospital blood and marrow transplant (BMT) program.Case CCC Protocol Templates Mandatory By 1/1/2013
The Case CCC SOP protocol templates (short and long versions) are available on the Case CCC website at: http://cancer.case.edu/researchadmin/forms/. They may also be accessed through links on the Clinical Research Portal or Clinical Trials Core Facility.
Effective immediately, protocol templates are considered a standard when developing investigator-initiated protocols which should contain all the necessary protocol template elements. Starting January 1, 2013, all investigators-initiated protocols will have to conform to the templates. Investigators are strongly encouraged to start using the templates as soon as possible and to provide feedback, so that the templates can be modified to better serve the needs of the Case CCC research community.
If you have any questions about the templates and/or to provide feedback, please contact Katarzyna Karelus at 216.844.4176 or email@example.com.Message from Dr. Pamela Davis, Dean CWRU SOM
The University Hospitals "Legacy" publication for Winter, 2011-2012 states that the UH Seidman Cancer Center carries a "National Cancer Institute designation as a Comprehensive Cancer Center."
The UH Seidman Cancer Center does not have NCI designation as a Comprehensive Cancer Center. This designation, and the grant from the National Cancer Institute, comes to Case Western Reserve University.
The UH Seidman Cancer Center is part of the Case Comprehensive Cancer Center, as is the Taussig Cancer Institute at The Cleveland Clinic. Case Western Reserve University is proud of the region-wide collaboration we have achieved to advance research and discovery for patients in Northeast Ohio.
FUNDING OPPORTUNITIESCTSC Annual Pilot Funding Competition
The Clinical and Translational Science Collaborative (CTSC) of CWRU and the Case Coulter Translational Research Partnership (CCTRP) is accepting letters of intent for 2012 CTSC Annual Pilot Grant Funding. The grant will fund up to $50,000 to support innovative translational research projects focused upon the invention, preclinical development and/or first in man studies of novel therapeutic agents, biomedical devices and diagnostics designed to address unmet clinical needs.
Investigators in the basic science and clinical departments at CWRU, Cleveland Clinic, MetroHealth Medical Center, UH and the Louis Stokes Cleveland VA Medical Center are eligible. The PI is required to be a faculty member from one of the five CTSC partner institutions and eligible to be a PI for an NIH grant.
Deadline Extended: January 17St. Baldrick's Foundation
St. Baldrick's Foundations is accepting applications for itsSpring 2012 grant cycle through a limited submission process. Grants are offered in six funding categories for childhood cancer research:
Internal Deadline: January 17
This year, the Samuel Waxman Cancer Research Foundation (SWCRF) will offer several two-year grants to individual investigators. Grantees will have the opportunity to extend their award to three years upon demonstration of successful collaborative efforts with existing members of the SWCRF Institute Without Walls. This RFA will focus on the pursuit of novel compounds, targets, and therapies.
Specific themes of interest to the SWCRF include studies that address:
Internal Deadline: February 1
The Case CCC is encouraging investigators to submit Letters of Intent for the Protocol Specific Research Support funding for Year 2012. The budgeted funds are for the conduct of early phase clinical trials and restricted to support research nurses and data managers directly involved in the conduct of these clinical trials. Studies developed jointly between UH and CCF with planned accrual at both institutions will be prioritized. Please direct questions and requests for information about the funding process to Katarzyna Karelus, Administrative Director, Case CCC Clinical Research Office, at 216.844.4176 or firstname.lastname@example.org.
NCI CANCER BULLETINJanuary 10, 2012
**All events are open to anyone interested in attending
Cancer Biology Seminar
Berman Lecture/Department of Medicine Grand Rounds
Immunology Seminar Series
Hematology and Oncology Division Research Conference
Immunology Faculty Research in Progress Series
OnCore Clinical Trials Management System Training Classes
Cancer Center/NCRM Special Seminar
Hem/Onc Fellows Conference
Taussig Cancer Institute Grand Rounds
Cancer Center Seminar Series
Cancer Center Research in Progress Seminar
Case CCC Calendar
UPCOMING CANCER CENTER SYMPOSIUMS & EVENTS
Cancer Cell Signaling Program Retreat
ADDITIONAL UPCOMING SEMINARS & EVENTS
Department of Biomedical Engineering Special Seminar
NCI Second Symposium on Translational Genomics
PREVIOUSLY ANNOUNCED OPPORTUNITIES
Caring for Carcinoid Foundation-AACR Grants for Carcinoid Tumor and Pancreatic Neuroendocrine Tumor Research
Leukemia & Lymphoma Society Translational Research Program
NIH BULLETIN – Notices and Funding Opportunities
Pediatric Phase 1/Pilot Consortium (Limited Competition UM1)(RFA-CA-12-502)
Molecular Characterization of Salivary Gland Tumors (R01)(RFA-DE-12-011)
Molecular Characterization of Salivary Gland Tumors (R21)(RFA-DE-12-012)
Request for Information (RFI): U. S.-China Collaborative Cancer Research in Complementary and Alternative Medicine (NOT-CA-12-009)
HELP US HELP YOU!
If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades!
Send items to email@example.com.